Location matters: Osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo

Clinical and Experimental Metastasis

Volumn 29, Issue 8, 2012, Pages 927-938

  Brown, H K ^a   Ottewell, P D ^a   Evans, C A ^a   Holen, I ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bone metastasis; Bone microenvironment; Breast cancer; Osteoblast; Osteoclast; Osteolysis

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; TRABECULAR BONE; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BONE; BONE TUMOR; BREAST TUMOR; CELL COMMUNICATION; CELL COUNT; CELL DIFFERENTIATION; CELL SIZE; GENETIC MARKER; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

BONE MORPHOGENETIC PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; SOST PROTEIN, HUMAN; TNFSF11 PROTEIN, MOUSE;

ANIMALS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL COMMUNICATION; CELL COUNT; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SIZE; FEMALE; GENETIC MARKERS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OSTEOBLASTS; OSTEOCLASTS; RANK LIGAND; TUMOR MICROENVIRONMENT;

EID: 84872876238     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9481-5     Document Type: Article

References (32)

1. Mundy GR (1997) Mechanisms of bone metastasis. Cancer 80(8 Suppl):1546-1556
2. Green JR (2003) Antitumor effects of bisphosphonates. Cancer 97(3 Suppl):840-847
3. Coxon FP, Helfrich MH, Van't Hof R et al (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15(8):1467-1476
4. Dunford JE, Thompson K, Coxon FP et al (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296(2):235-242
5. Roelofs AJ, Thompson K, Ebetino FH et al (2010) Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 16(27):2950-2960
6. van Beek E, Pieterman E, Cohen L et al (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264(1):108-111
7. Fromigue O, Lagneaux L, Body JJ (2000) Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15(11):2211-2221
8. Sasaki A, Boyce BF, Story B et al (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55(16):3551-3557
9. van der Pluijm G, Que I, Sijmons B et al (2005) Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 65(17):7682-7690
10. Yoneda T, Michigami T, Yi B et al (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88(12 Suppl):2979-2988
11. Croucher PI, De Hendrik R, Perry MJ et al (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18(3):482-492
12. Daubine F, Le Gall C, Gasser J et al (2007) Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99(4):322-330
13. Hiraga T, Williams PJ, Ueda A et al (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10(13):4559-4567
14. Corey E, Brown LG, Quinn JE et al (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9(1):295-306
15. Phadke PA, Mercer RR, Harms JF et al (2006) Kinetics of metastatic breast cancer cell trafficking in bone. Clin Cancer Res 12(5):1431-1440
16. Ottewell PD, Monkkonen H, Jones M et al (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100(16):1167-1178
17. Chantry AD, Heath D, Mulivor AW et al (2010) Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo. J Bone Miner Res 25(12):2633-2646
18. Deleu S, Lemaire M, Arts J et al (2009) Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Res 69(13):5307-5311
19. Heath DJ, Chantry AD, Buckle CH et al (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24(3):425-436
20. Mohanty ST, Kottam L, Gambardella A et al (2010) Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis. Arthritis Res Ther 12(4):R149
21. Trebec DP, Chandra D, Gramoun A et al (2007) Increased expression of activating factors in large osteoclasts could explain their excessive activity in osteolytic diseases. J Cell Biochem 101(1):205-220
22. Clohisy DR, Palkert D, Ramnaraine ML et al (1996) Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis. J Orthop Res 14(3):396-402
23. Clohisy DR, Ogilvie CM, Carpenter RJ et al (1996) Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts. J Orthop Res 14(1):2-6
24. Dhurjati R, Krishnan V, Shuman LA et al (2008) Metastatic breast cancer cells colonize and degrade three-dimensional osteoblastic tissue in vitro. Clin Exp Metastasis 25(7):741-752
25. Bodenstine TM, Beck BH, Cao X et al (2011) Pre-osteoblastic MC3T3-E1 cells promote breast cancer growth in bone in a murine xenograft model. Chin J Cancer 30(3):189-196
26. Huang Z, Cheng SL, Slatopolsky E (2001) Sustained activation of the extracellular signal-regulated kinase pathway is required for extracellular calcium stimulation of human osteoblast proliferation. J Biol Chem 276(24):21351-21358
27. Shiozawa Y, Pedersen EA, Havens AM et al (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121(4):1298-1312
28. Vukmirovic-Popovic S, Colterjohn N, Lhotak S et al (2002) Morphological, histomorphometric, and microstructural alterations in human bone metastasis from breast carcinoma. Bone 31(4):529-535
29. Armstrong AP, Miller RE, Jones JC et al (2008) RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate 68(1):92-104
30. Mendoza-Villanueva D, Zeef L, Shore P (2011) Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFbeta-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res 13(5):R106
31. Kinder M, Chislock E, Bussard KM et al (2008) Metastatic breast cancer induces an osteoblast inflammatory response. Exp Cell Res 314(1):173-183
32. Coleman RE, Marshall H, Cameron D et al (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365(15):1396-1405